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Abstract
Background: Previously, we determined that heterogeneous nuclear ribonucleoprotein E1 (hnRNP-E1) functions as an
intracellular physiologic sensor of folate deficiency. In this model, L-homocysteine, which accumulates intracellularly in
proportion to the extent of folate deficiency, covalently binds to and thereby activates homocysteinylated hnRNP-E1 to
interact with folate receptor-a mRNA; this high-affinity interaction triggers the translational upregulation of cell surface
folate receptors, which enables cells to optimize folate uptake from the external milieu. However, integral to this model is
the need for ongoing generation of hnRNP-E1 to replenish homocysteinylated hnRNP-E1 that is degraded.
Objective: We searched for an interrelated physiologic mechanism that could also maintain the steady-state
concentration of hnRNP-E1 during prolonged folate deficiency.
Methods: A novel RNA-protein interaction was functionally characterized by using molecular and biochemical approaches
in vitro and in vivo.
Results: L-homocysteine triggered a dose-dependent high-affinity interaction betweenhnRNP-E1 and a 25-nucleotide cis element
within the 5#-untranslated region of hnRNP-E1mRNA; this led to a proportionate increase in these RNA-protein complexes, and
translation of hnRNP-E1 both in vitro and within placental cells. Targeted perturbation of this RNA-protein interaction either by
specific 25-nucleotide antisense oligonucleotides or mutation within this cis element or by small interfering RNA to hnRNP-E1
mRNA significantly reduced cellular biosynthesis of hnRNP-E1. Conversely, transfection of hnRNP-E1 mutant proteins that
mimicked homocysteinylated hnRNP-E1 stimulated both cellular hnRNP-E1 and folate receptor biosynthesis. In addition, ferrous
sulfate heptahydrate [iron(II)], which also binds hnRNP-E1, significantly perturbed this L-homocysteine–triggered RNA-protein
interaction in a dose-dependent manner. Finally, folate deficiency induced dual upregulation of hnRNP-E1 and folate receptors in
cultured human cells and tumor xenografts, and more selectively in various fetal tissues of folate-deficient dams.
Conclusions: This novel positive feedback loop amplifies hnRNP-E1 during prolonged folate deficiency and thereby
maximizes upregulation of folate receptors in order to restore folate homeostasis toward normalcy in placental cells. It will
also functionally impact several other mRNAs of the nutrition-sensitive, folate-responsive posttranscriptional RNA operon
that is orchestrated by homocysteinylated hnRNP-E1. J Nutr 2017;147:482–98.
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Introduction
Folate deficiency triggers the upregulation of folate receptors,
which serves to optimize cellular folate uptake and help restore
folate homeostasis to normal (1, 2). The molecular basis for
upregulation of folate receptors likely involves the progressive
homocysteinylation of heterogeneous nuclear ribonucleoprotein
E1 (hnRNP-E1)10 in proportion to the degree of folate deficiency
(3), with replacement of key cysteine S–S cysteine disulfide bonds in
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hnRNP-E1 by homocysteine S–S cysteine mixed disulfide bonds,
which results in the gradual unmasking of an underlying mRNA-
binding site in hnRNP-E1. This allows homocysteinylated hnRNP-E1
to bind with high affinity to an 18-nucleotide cis element in the
5#-untranslated region (5#-UTR) of folate receptor a mRNA,
which, in turn, leads to a proportionate translational upregula-
tion of folate receptors (3). Thus, hnRNP-E1, which is able to
sense the level of intracellular folate deficiency and proportion-
ately respond by increasing folate receptor a expression, has been
incriminated as a physiologic cellular sensor of folate deficiency
(2, 3). Because hnRNP-E1 assumes such a critical role to ensure
folate homeostasis (2, 3), there is a simultaneous need for ongoing
generation of newly synthesized hnRNP-E1 that can replenish
homocysteinylated hnRNP-E1, which is degraded with a half-life
of 52 h (3), particularly during prolonged periods of folate de-
ficiency. This raises the possibility of an interrelated physiologic
mechanism for the coexpression of hnRNP-E1 with folate recep-
tors. Such an occurrence could explain clinical observations in
which folate receptors and hnRNP-E1 are concordantly overex-
pressed in various human and murine tissues (1, 4–13).
The mRNA-binding site within homocysteinylated hnRNP-E1
is promiscuous because there are several diverse mRNAs with
common poly(rC)/poly(U)–rich RNA cis elements that can
also interact with this protein (14–16). Together, these mRNAs
comprise a nutrition-sensitive, folate-responsive, posttranscriptional
RNA operon that is orchestrated by homocysteinylated hnRNP-E1
(3). Many of these functionally distinct mRNAs likely contribute to
the plethora of progressive pathobiological changes observed as cells
experience mild, moderate, and severe folate deficiency. Morpho-
logically, these developing megaloblastic changes, which are most
apparent in rapidly proliferating cells, exhibit features of nuclear-
cytoplasmic dissociation (involving asynchrony of nuclear and
cytoplasmic maturation), with reduced cell proliferation because of
varying degrees of cell cycle arrest and apoptosis—the end result of
prolongedmegaloblastosis (2). These distinct cellular changes during
folate deficiency necessitate the coordinated involvement of several
functionally diverse genes. In this context, it is therefore plausible
that the progressive homocysteinylation of hnRNP-E1 during folate
deficiency is also capable of modulating diverse mRNAs that
belong to this novel posttranscriptional RNA operon.
Therefore, we focused on determining themechanismwhereby
the concentration of hnRNP-E1 was maintained during pro-
longed folate deficiency. Accordingly, we searched for evidence that
favored a specific physiologic interaction of hnRNP-E1 with
common poly(rC)/poly(U)–rich RNA cis elements within its own
hnRNP-E1 mRNA in vitro, and in response to prolonged folate
deficiency in vivo. Then we sought evidence for dual activation of
hnRNP-E1 mRNA and folate receptor a mRNA by homocystei-
nylated hnRNP-E1, both in vitro and in vivo.
Methods
Materials. All reagents of the highest available purity were purchased
from Sigma-Aldrich. All cell culture media and other additives, Dulbeccos
PBS, Escherichia coli DH10B-competent bacteria, and oligonucleotides
were from Invitrogen. [a-32P]UTP (specific activity >3000 Curie/mmol)
and L-[35S]methionine or L-[35S]cysteine (in vitro translation grade) were
from Perkin-Elmer. Restriction endonucleases were from Roche Applied
Science. L-homocysteine (98% purity) was from Sigma-Aldrich.
Culture of placental cell lines. The human placental cell lines (1584,
JAR, and CCL-98), obtained from American Type Culture Collection,
were propagated long-term in high-folate (HF) media (DMEM-HF),
which contained nondialyzed 10% FBS, and 9.1-mmol/L folic acid plus
13.6-nmol/L 5-methyl-tetrahydrofolate (3). These cells were then slowly
adapted to growth in physiologically low-folate (LF) media (DMEM-LF),
which contained no added folic acid in the media, nondialyzed 10% FBS,
and 13.6 nM 5-methyl-tetrahydrofolate, for 14 wk, after which both
mRNA and protein for folate receptor and hnRNP-E1 were evaluated (1).
Folate receptor a and hnRNP-E1RNA fromHF and LF placental cells was
determined by qRT-PCR.
Expression of the glutathione S-transferase fusion protein from
recombinant glutathione S-transferase–hnRNP-E1 and its mutants.
Recombinant glutathione S-transferase (GST)–plasmid DNA, pGST–
hnRNP-E1, pGST–hnRNP-E2, and related mutated plasmids (3) were
transformed into BL21 E. coli from Novagen. After induction by 1 mM
isopropyl-1-thio-b-D-galactopyranoside, the GST–hnRNP-E1 andmutated
fusion proteins were individually purified with the use of the B-PER GST
Fusion Protein Purification Kit (Pierce). The eluted GST fusion proteins
were dialyzed against 500 volumes of buffer to remove excess reducing
reagents (such as DTT) and assayed by SDS-PAGE andWestern blots with
the use of anti-peptide hnRNP-E1 antiserum (5). Gel-shift assays with
target RNAwere carried out as described (3).
Preparation of 25-nucleotide hnRNP-E1 mRNA cis element and
related constructs. To prepare the 25-nucleotide hnRNP-E1 mRNA
cis element, pSPT18–25 DNA was obtained by subcloning a pair of
oligodeoxynucleotides (5#-g CTCCCGCCCGCTCCCGCTCGCTCC
C g-3# and 5#-aattc GGG AGC GAG CGG GAG CGG GCG GGA
Gctgct-3#) into pSPT18 vector linearized with PstI and EcoRI. To
prepare the 25-nucleotide hnRNP-E1 mRNA cis element proximal to
hnRNP-E1 mRNA, pSPT18–25–hnRNP-E1 DNA was obtained by
subcloning the PCR product from Gene Pool cDNA (Human Placenta
cDNAs; Invitrogen) into pSPT18. The PCR product from Gene Pool
cDNA was digested with PstI and EcoRI, and then ligated to pSPT18
plasmid linearized with PstI andEcoRI. The primers used in PCRwere as
follows: 5#-tgacctgcag GAC TCC CGC CCG CTC-3# and 5#-tgacgaattc
CTA GCT GCA GGG CAT GC-3#.
To incorporate the 25-nucleotide hnRNP-E1 cis element proximal
to a chloramphenicol acetyltransferase (CAT) reporter (pCAT-25) and a
control 25-nucleotide scrambled sequence proximal to CAT (pCAT-25-
scrambled), 2 pairs of oligodeoxynucleotides were subcloned into
pCAT3-control vector that was linearized with NheI and BglII to
generate pCAT-25 and pCAT-25-scrambled vectors. Oligodeoxynucleo-
tides for 25-nucleotide hnRNP-E1 cis element inserts were as follows:
5#-ctagc CTC CCGCCCGCTCCCGCTCGCTCCC a-3# and 5#-gatct
GGG AGC GAG CGG GAG CGG GCG GGA G g-3#. Oligodeoxy-
nucleotides for the 25-nucleotide scrambled insert sequence were as
follows: 5#-ctagc GCG TCG CTC GCT TCG CAC GTG CGC C a-3#
and 5#-gatct GGC GCA CGT GCG AAG CGA GCG ACG C g-3#.
RNA-protein binding assays. RNA-protein binding assays involved
incubation of one of various radiolabeled target RNAs {1 3 105
counts per minute of [35S]25-nucleotide hnRNP-E1 mRNA cis element,
10 Abbreviations used: CAT, chloramphenicol acetyltransferase; FAM, 5#6-
carboxyfluorescein; GST, glutathione S-transferase; HA, highest affinity; HF,
high-folate; hnRNP-E1, heterogeneous nuclear ribonucleoprotein E1; HPV16,
human papillomavirus type 16; iron(II), ferrous sulfate heptahydrate; iron(III),
ferric chloride hexahydrate; JOE, 6-carboxy-4#,5#-dichloro-2#,7#-dimethoxyfluorescein;
KD, dissociation constant; LF, low-folate; neurofilament M, neuronal intermediate
neurofilament–middle molecular mass; siRNA, small interfering RNA; 5#-UTR,
5#-untranslated region.
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or [35S]18-nucleotide folate receptor amRNA cis element (3), or human
papillomavirus type 16 (HPV16) [35S]L2 RNA cis element (17)} with
either purified 0.5-mg dialyzed purified recombinant GST–hnRNP-E1 or
its mutants, in standard buffer (3) in the absence or presence of various
concentrations of physiologically and nonphysiologically relevant thiols
(b-mercaptoethanol, glutathione, methionine, L-cysteine, L-homocysteine,
and DTT), as described (1, 3, 17). Parenthetically, there was no
significant difference in RNA binding to GST–hnRNP-E1 by use of
either 32P-RNA probes (3) or 35S-labeled RNA probes used in this
paper (data not shown).
Effects of ferrous sulfate heptahydrate on the homocysteine-
induced RNA-protein interaction. Studies were also conducted to
evaluate the effect of ferrous sulfate heptahydrate [iron(II)] or ferric
chloride hexahydrate [iron(III)] in modulating RNA-protein interactions
during gel-shift assays in either the absence or presence of 10-mmol
glutathione/L. The iron preparation, either alone or with 50 mmol
deferoxamine/L to define the specificity of iron(II), was incubated first
with glutathione and hnRNP-E1 before the addition of other compo-
nents of the reaction mixture. Briefly, RNA-protein binding and gel-shift
assays were carried out with purified recombinant GST–hnRNP-E1
protein and [35S]25-nucleotide hnRNP-E1mRNA cis element in binding
buffer and 5-mmol L-homocysteine/L plus increasing concentrations of
iron(II) or iron(III) (0–25 mmol/L). The samples were analyzed by
polyacrylamide gel electrophoresis and autoradiography overnight
followed by densitometric analysis of the signals representing RNA-
protein complexes.
In vitro transcription/translation studies. In vitro transcription/
translation was carried out with the use of the Linked SP6/T7 In Vitro
Transcription/Translation Kit (Roche Applied Science) after the addition
of one of various targeted DNAs—pSPT18-25–hnRNP-E1 DNA, or
PstI-linearized plasmid pSPT18–folate receptor a (5, 18), or HPV16 L2
DNA (17), (0.5 mg/reaction)—to the transcription mix as described (1, 3).
In other experiments, the capacity for perturbing the interaction of
hnRNP-E1 with the 25-nucleotide hnRNP-E1 cis element during in vitro
translation was assessed in the presence of either scrambled oligonucle-
otides (5#- GCG TCG CTC GCT TCG CAC GTGCGC C-3#) or specific
antisense oligonucleotides (5#-GGG AGC GAG CGG GCG GGA G-3#)
generated against the 25-nucleotide hnRNP-E1 mRNA cis element
(GenScript USA). Glutathione was not added when the effect of iron(II)
was assessed during in vitro translation because the commercial
reticulocyte lysate contained 4.1-mmol b-mercaptoethanol/L.
Dissociation constant of various RNA-protein interactions. The
influence of either L-homocysteine or L-cysteine on the dissociation
constant (KD) of the RNA-protein interaction was assessed in the
absence and presence of physiologic concentrations of glutathione
(10-mmol/L) with the use of previously described methods (3). Specific
binding was determined by subtracting values of nonspecific binding
with GST from those of total binding with purified recombinant GST–
hnRNP-E1; however, nonspecific binding with the use of BSA was
subtracted from total binding to GST–hnRNP-E1 to determine specific
binding in Tables 1 and 2. The KD was calculated from a Scatchard plot
with the use of GraphPad Prism 6, as described (3).
qRT-PCR to determine RNA expression of hnRNP-E1 and folate
receptor a in cells. Total RNAwas separately extracted from placental
1584-HF and 1584-LF cells. Gene expressionwas determined on triplicate
RNA samples (50 ng/reaction)with the use of an Invitrogen SuperScript III
PlatinumOne-Step qRT-PCR kit and an ABI 7900HT Sequence Detection
System (PE Biosystems). The cycle conditions were as follows: after a first
step of 15 min at 50C and 10 min at 95C, the samples were cycled 40
times at 95C for 15 s and at 60C for 60 s. For all quantitative analyses,
we used the comparative cycle threshold method by following the PE
Biosystems protocol. The specific primers were obtained from Invitrogen
with fluorogenic labels either 5#6-carboxyfluorescein (FAM) or
6-carboxy-4#,5#-dichloro-2#,7#-dimethoxyfluorescein (JOE). Primers for
hnRNP-E1 were 5#-GAC GCC GGA GAC TGG GAG AGC G [FAM]
C-3#and 5#-GGA TAT GCT GCC CAA CTC CA-3#. Primers for folate
receptor a were 5#-GAA CCT ATG AGG AGG TGG CGA GG [FAM]
TC-3# and 5#-TAG GGC CAG GCT AAG CAG GA-3#. Primers for
GAPDHwere 5#-CAACAGGAGGAGTGGGTGTCGCTG (JOE)TG -3#
and 5#-GGC ATC CTG GGC TAC ACT GA-3#. Primers to the
hnRNP-E1 gene or folate receptor a gene (labeled with FAM) and
primers to a housekeeping gene GAPDH (labeled with JOE) were
run in parallel, respectively, to standardize the input amount. Controls
consisting of ribonuclease-free water were negative in all runs.
Effects of L-homocysteine on various CAT reporter constructs
transfected into placental 1584-HF cells. To prepare pCAT-25 or
pCAT-25-mutant, 2 pairs of oligonucleotides, 1 for pCAT-25 (5#-
tagcaggtac AAG CTT CTC CCG CCC GCT CCC GCT CGC TCC CCA
TGG tgtaactagct-3#; 5#-agctagttaca CCA TGG GGA GCG AGC GGG
AGC GGG CGG GAG AAG CTT gtacctgcta-3#), and 1 for pCAT-25
mutant no. 6 (5#-tagcaggtac AAGCTT CTT CCGCCCGCT CCCGCT
CGC TTC CCA TGG tgtaactagct-3#; 5#-agctagttaca CCA TGG GGA
GCG AGCGGGAGC GGGCGGGAG AAG CTT gtacctgcta-3#), were
first linearized withHindIII andNcoI and subcloned into pCAT3 control
DNA digested with HindIII and NcoI. After transient transfection of
either pCAT-25 or pCAT-25 mutant no. 6 plasmid DNA together with
pSV-b-gal DNA into placental 1584-HF cells, these cells were incubated
with physiologically relevant concentrations of L-homocysteine, and net
CAT expression was assessed as described (3).
Capture of RNA-protein complexes within cells. Slot-blot hybrid-
ization was carried out under high stringency conditions to detect
intracellular RNA-protein complexes (composed of endogenous
hnRNP-E1 RNA cis element–bound to cellular hnRNP-E1 proteins) in
placental 1584 cells under experimental conditions that modulated the
intracellular concentration of homocysteine. We used principles similar
to those used to capture folate receptor a mRNA cis element–bound
hnRNP-E1 complexes in HeLa-IU1 cells (3). Briefly, after L-homocysteine
treatment, the extant intracellular RNA-protein complexes were
UV-crosslinked and isolated on anti–hnRNP-E1 antiserum–linked aga-
rose. After ribonuclease treatment and proteolysis, equal aliquots of the
released small mRNA cis element fragments were probed for evidence of
enrichment of hnRNP-E1 mRNA cis element in experimental cells with
the use of a specific [35S]-labeled antisense hnRNP-E1 mRNA cis
element probe (3).
Transfection of antisense oligonucleotides to the 25-nucleotide
hnRNP-E1 cis element on the biosynthetic rate of hnRNP-E1
proteins in cells. On the day before transfection, placental 1584-HF
cells were trypsinized, counted, and plated in 6-well plates at 2 3 105
cells per well in 2.5 mL MEM-HF medium, so that cells would be 70–
80% confluent after overnight culture. Cells were then transfected with
either wild-type or scrambled DNA or antisense DNA to 25-nucleotide
hnRNP-E1 cis element with the use of Lipofectamine 2000 DNA
transfection reagent and the manufacturers protocol. One well of cells
TABLE 1 Comparison of the KD of the interaction of
recombinant purified GST–hnRNP-E1 or its mutant protein for the
[35S]25-nucleotide hnRNP-E1 mRNA cis-element in the absence
or presence of L-homocysteine1
Protein L-homocysteine, mM KD, nM
GST–hnRNP-E1 0 1.93 6 0.18a
GST–hnRNP-E1 10 1.14 6 0.17b
GST–hnRNP-E1 50 0.62 6 0.10c
GST–hnRNP-E1(G292A) 0 2.02 6 0.19a
GST–hnRNP-E1(C293S) 0 0.39 6 0.04d
1 Values are means 6 SDs, n = 3 (means of triplicates). Labeled means without a
common superscript letter differ, P, 0.05. GST, glutathione S-transferase; hnRNP-E1,
wild-type heterogeneous nuclear ribonucleoprotein E1; hnRNP-E1(C293S), highest
affinity–heterogeneous nuclear ribonucleoprotein E1 (C293S)–mutant protein; hnRNP-
E1(G292A), wild-type–like heterogeneous nuclear ribonucleoprotein E1 (G292A)–mutant
protein; KD, dissociation constant.
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was trypsinized and harvested on day 3 [2 d after transfection] as a control.
Cells in the remaining 5 wells were starved of cysteine with the use of
cysteine-free MEM-HF for 4 h, after which the rate of biosynthesis of
hnRNP-E1 protein was determined in transfected cells by specifically
immunoprecipitating and quantifying newly synthesized [35S]hnRNP-E1 (3).
RNA interference of hnRNP-E1 mRNA on the biosynthetic rate of
hnRNP-E1 and folate receptor proteins in cells. Before the day of
small interfering RNA (siRNA) transfection, placental 1584-HF cells
were trypsinized, counted, and plated in 6-well plates at 1.4 3 105 cells
per well (;30–40% confluence) in 2.5 mL MEM-HF medium, so that
cells were 60–80% confluent after overnight culture. Cells were then
transfected over 2 d with either 10 nmol predesigned Stealth RNA
interference/L [siRNA–hnRNP-E1/poly(rC)-binding protein 1 (PCBP1)]
or 10 nmol scrambled negative stealth RNA interference control/L with
the use of Lipofectamine RNAiMAX transfection reagent and a minor
modification of the manufacturers protocol (3). One of these wells was
trypsinized and harvested 2 d after transfection, after which the RNA
was purified for qRT-PCR analysis of hnRNP-E1 RNA expression. Cells
in the remaining 5 wells were starved of cysteine for 4 h and the rate of
biosynthesis of newly synthesized [35S]hnRNP-E1 and [35S]folate recep-
tor proteins was determined, as described (3).
Determination of the biosynthetic rate of folate receptors or
hnRNP-E1 proteins in cells transfected with either wild-type or
various mutant hnRNP-E1 proteins. The transfection of purified
recombinant wild-type or various mutant hnRNP-E1 proteins into cells
was achieved with the use of the Xfect Protein Transfection Kit
(Clontech). Briefly, placental 1584-HF cells in 10-cm dishes at 70–
80% confluence were transfected with 2.4 mL serum-free medium and
Xfect Protein Transfection Reagent (1.2 mL) containing 20 mg either
wild-type hnRNP-E1-, or highest-affinity (HA) hnRNP-E1(C293S)
mutant, or wild-type–like hnRNP-E1(G292A) mutant proteins (de-
scribed in Supplemental Methods, Supplemental Results, Supplemental
Discussion, and Supplemental References) and 2 mg b-galactosidase at
37C for 60 min. After cysteine starvation for 4 h, an aliquot of cells was
assessed for b-galactosidase activity (to measure the efficiency of
cotransfection of b-galactosidase), and the remaining cells were pulsed
with L-[35S]cysteine (250 mCurie) and assessed for specific [35S]cysteine
incorporated into folate receptor to determine the biosynthetic rate of
this protein (3). A similar protocol was used for the analysis of newly
synthesized [35S]hnRNP-E1 with the use of anti–hnRNP-E1 antiserum–
coupled agarose and control agarose in order to derive values for specific
[35S]cysteine incorporated into hnRNP-E1 and thereby determine the
biosynthetic rate of this protein (3).
Mouse protocols and care. All mouse care procedures conformed to
the Guide for the Care and Use of Laboratory Animals (13). The protocols
for the use of athymic mice in experiments involving tumor xenografts were
approved by the Institutional Animal Care and Use Committee at Indiana
University–Purdue University at Indianapolis. To evaluate for upregulation
of folate receptors and hnRNP-E1 within cervical cancer xenograft tumors
that were generated in athymic mice, 6 athymic mice were fed a standard
folate-replete diet (1200 nmol folate/kg diet) and 5 athymic mice were fed a
severely folate-restricted diet (120 nmol folate/kg diet) for 4 wk (13) before
injection of 1 million HeLa-IU1 cells into their flanks (19). The tumors were
subsequently examined for hnRNP-E1 and folate receptor expression by
immunohistochemistry, northern blots, and western blots. For western blot
analyses of folate receptor and hnRNP-E1 expression in tumors, 50 mg
protein from HeLa-IU1–derived tumors was subjected to 10% SDS-PAGE
and western transfer followed by probing of nitrocellulose-bound
proteins with either anti-folate receptor antiserum or anti–hnRNP-E1
antiserum or anti-GAPDH antibodies (3). Total RNAwas obtained from
HeLa-IU1–derived tumors inmice fed a normal or LF diet. The hnRNP-E1
probe was excised from plasmid pGEX-4T-1–hnRNP-E1 with the use
of BamH1 and Not1 digestion. The folate receptor a plasmid was
digested with HindIII and EcoRI to liberate its cloned insert. DNA
fragments were gel-purified and labeled with the use of the Random
Primed Labeling Kit (Roche Applied Science) and [a-32P]deoxy-ATP (1).
Northern blots were carried out by electrophoresis of 20 mg RNA in
standard formaldehyde-agarose gels followed by transfer to Hybond-N+
nylon membranes (Amersham/GE Healthcare Biosciences) and UV
crosslinking. Membranes were hybridized with the 32P-labeled probes
and detected according to the manufacturer’s instructions (Roche
Applied Science). Ethidium bromide staining of 28S was monitored for
RNA quality, and b-actin was used as a loading control.
Mouse experiments with the use of CD-1 mice were conducted at the
National Center for Toxicological Research; these mouse studies were
approved by each of the local institutional animal care and use
committees in Arkansas and Indiana. The protocols for the procurement
and feeding of CD-1 mice (Charles River) with either a folate-replete diet
(1200 nmol folate/kg diet) or folate-deficient diet (400 nmol folate/kg
diet), breeding and dams killed on gestation day 17, removal and killing
of fetuses and fixation in formalin, histochemical staining, and analysis
of paraffin-embedded fetal tissues (13) were as described (3). The
placentas from dams that were fed a folate-deficient compared with a
folate-replete diet (3) were also examined for morphologic differences
after sectioning and staining. Images were captured with a Leitz DMLB
light microscope equipped with a Diagnostic Instruments Spot digital
camera (Diagnostic Instruments) and processed with the use of Adobe
Photoshop software. The localization of tissues in gestation day 17
fetuses was based on Kaufmans atlas (20).
Supplemental Methods. The following experiments can be found in
the Supplemental Methods: Site-directed mutagenesis of hnRNP-E1;
HPV16 L2 RNA-related gel-shift and in vitro translation; Determination
of the concentration of homocysteine, cystathionine, cysteine, and
methionine in placental cells; and Transfection of various CAT reporters
linked to hnRNP-E1 DNA or its mutants into Hela-IU1-HF cells.
Statistical analyses. All of the statistical analyses were conducted with
the use of GraphPad Prism 6. Unless otherwise specified, results are
expressed as means 6 SDs, n = 3 (means of triplicates). Comparisons
between 2 groups were analyzed by Students t test and comparisons
between multiple groups was analyzed with the use of 1-factor ANOVA
followed by a Tukeys test. The statistical significance was set at P < 0.05.
Results
Characterization of a 25-nucleotide cis element in the 5#-
UTR of hnRNP-E1 mRNA that interacts with hnRNP-E1.
The gene sequence of hnRNP-E1 revealed a candidate 25-
nucleotide poly(rC)-rich region in the 5#-UTR of hnRNP-E1,
from 2145 to 2120 upstream of the start site of the coding
sequence of hnRNP-E1 (Figure 1A). This candidate hnRNP-E1
cis element had a structural organization similar to that noted
within the 18-nucleotide folate receptor a mRNA cis element
(18), which consisted of a tandem CUCC sequence separated by
6–8 bases as a putative protein binding motif; likewise, the
hnRNP-E1mRNA cis element contained 3 such CUCC sequence
motifs. Therefore, we focused on the potential for binding be-
tween homocysteinylated hnRNP-E1 and this 25-nucleotide cis
TABLE 2 Dose-dependent influence of iron(II) on the KD
involving the L-homocysteine–triggered RNA-protein interaction
between the [35S]25-nucleotide hnRNP-E1mRNA cis element and
purified recombinant GST–hnRNP-E1 protein1
Protein Iron(II), mM L-homocysteine, mM KD, nM
GST–hnRNP-E1 0 25 2.74 6 0.52a
GST–hnRNP-E1 5 25 3.72 6 0.34b
GST–hnRNP-E1 25 25 6.50 6 0.83c
1 Values are means 6 SDs, n = 3 (means of triplicates). Labeled means without a
common superscript letter differ, P, 0.05. GST, glutathione S-transferase; hnRNP-E1,
wild-type heterogeneous nuclear ribonucleoprotein E1; iron(II), ferrous sulfate
heptahydrate; KD, dissociation constant.
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element in the 5#-UTR of hnRNP-E1 mRNA to determine if this
RNA-protein interaction led to enhanced translation of hnRNP-E1
in vitro and in cultured placental cells.
Gel-shift assays showed a dose-dependent increase of RNA-
protein signal with increasing physiologically relevant concentrations
of L-homocysteine (Figure 1B, lanes 6–10). The involvement of
hnRNP-E1 in RNA-protein complexes was shown by a super-
shift of the RNA-protein signal with anti–hnRNP-E1 antise-
rum (Figure 1B, lane 1); no such supershift was noted
when nonimmune serum was used (not shown). Supplemental
Figure 1 and Supplemental Results contain data that confirm
the specificity of the anti–hnRNP-E1 antiserum used in these
studies. The reticulocyte lysate mixture used for in vitro
translation contains small quantities of hnRNP-E1 (8, 9, 11,
12, 21). Accordingly, we evaluated the functional conse-
quences of interaction of the 25-nucleotide hnRNP-E1
mRNA cis element and (endogenous) hnRNP-E1 during
in vitro translation. Quenching excess b-mercaptoethanol in
the translation mixture with N-ethylmaleimide (Figure 1C,
lane 2–4) led to a progressive reduction in the amount of
hnRNP-E1 translated compared with the baseline hnRNP-E1
signal (Figure 1C, lane 1). Maintaining N-ethylmaleimide in
the reaction mixture improved the sensitivity of the system
to the subsequent addition of physiologic concentrations of
L-homocysteine, which led to a progressively increased transla-
tion of hnRNP-E1 (Figure 1C, lanes 5–7). The specific involve-
ment of endogenous hnRNP-E1 in mediating the translation of
hnRNP-E1 was confirmed by the dose-dependent quenching of
FIGURE 1 Characterization of the interaction of a 25-nucleotide cis element in the 5#-UTR of hnRNP-E1 with hnRNP-E1 in vitro. Location of the
candidate 25-nucleotide cis element (bold, capitalized, and underlined) in the 5#-UTR of hnRNP-E1 from2145 to2120 from the ATG start site (A).
Gel-shift analysis of the interaction of radiolabeled 25-nucleotide hnRNP-E1mRNA cis element and purified recombinant GST–hnRNP-E1 (lanes 1,
3, and 6–10) or hnRNP-E1 mutants (lanes 4 and 5) in the absence or presence of L-homocysteine; supershift of the RNA-protein signal with anti–
hnRNP-E1 antiserum (lane 1) (B). In vitro translation of hnRNP-E1 after quenching excess thiols in the reaction mixture by NEM (lane 2–4) to
assess the effect of increasing L-homocysteine (lanes 5–7), and comparison of the independent effect of wild-type or mutant hnRNP-E1 (lanes
8–10) (C). Demonstration of the key role of hnRNP-E1 in mediating in vitro translation of hnRNP-E1 protein by the addition of anti–hnRNP-E1
antiserum (lanes 4–7) (D). Lanes 1 and 2 were internal protein controls. Comparison of the effectiveness of antisense oligonucleotides to the
25-nucleotide hnRNP-E1 cis element and scrambled oligonucleotides in quenching the translation of hnRNP-E1 in vitro (E). The autoradiograms
shown in B, C, D, and E are representative of 3 separate experiments, and pooled densitometric scanned data of signals are compared with the
100% value. Values are means6 SDs, n = 3 (means of triplicates). Labeled means without a common letter differ, P, 0.05. Ab, antiserum; GST,
glutathione S-transferase; hnRNP-E1, wild-type heterogeneous nuclear ribonucleoprotein E1; hnRNP-E1(G292A), wild-type–like heterogeneous
nuclear ribonucleoprotein E1 (G292A) mutant; hnRNP-E1(C293S), highest affinity–heterogeneous nuclear ribonucleoprotein E1 (C2923S) mutant;
NEM, N-ethylmaleimide; nt, nucleotide; 5#-UTR, 5#-untranslated region.
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the signal with the addition of increasing concentrations of anti–
hnRNP-E1 antiserum (Figure 1D, lanes 5–7); by contrast, there
was no effect of anti–hnRNP-E1 antiserum on the translation
of internal control DNA (lane 1 compared with 2), and no
reduction in translation of hnRNP-E1 by nonimmune serum
(lane 9).
The experiments that led to the selection of the most effective
molecular mimic of homocysteinylated hnRNP-E1 and its
control that was used to further characterize the interaction of
hnRNP-E1 with its own cis element are described in the
Supplemental Methods, Supplemental Results, and Supplemen-
tal Table 1. Thus, Supplemental Figure 2 demonstrated that the
mutation of cysteine 293 to serine in the third K-homology
domain of hnRNP-E1 resulted in the highest affinity for the
folate receptor a mRNA cis element and for HPV16 L2 cis
element, even in the absence of L-homocysteine, which also led
to expected functional outcomes (3, 17); this mutant is hereafter
referred to as the (HA)-hnRNP-E1(C293S) mutant. By contrast,
mutation of the adjacent glycine-292 to alanine failed to confer
such properties, and this mutant protein behaved similarly to
wild-type hnRNP-E1 in that interaction with these target cis ele-
ments was increased only upon the addition of L-homocysteine;
hence, this control was referred to as a wild-type–like hnRNP-E1
(G292A) mutant. Thus, as also shown in Figure 1B, incubation
of 25-nucleotide hnRNP-E1 RNA cis element with wild-type
hnRNP-E1 and wild-type–like hnRNP-E1(G292A) mutant in the
absence of L-homocysteine (lanes 3 and 4) revealed noRNA-protein
gel-shift signals, but there was a strong signal when 25-nucleotide
hnRNP-E1mRNA cis element reacted with (HA)-hnRNP-E1(C293S)
mutant (lane 5), even in the absence of L-homocysteine. Moreover,
after b-mercaptoethanol was neutralized by N-ethylmaleimide,
only the (HA)-hnRNP-E1(C293S) mutant markedly stimulated the
translation of hnRNP-E1 in vitro (Figure 1C, lane 10) compared
with wild-type hnRNP-E1 and wild-type–like hnRNP-E1(G292A)
mutant (lanes 8, 9).
Specific antisense oligonucleotides to the 25-nucleotide
hnRNP-E1 mRNA cis element led to a dose-dependent inhibi-
tion of translation of hnRNP-E1, as shown in Figure 1E (lanes
2–4). By contrast, scrambled oligonucleotides failed to quench
the translation of hnRNP-E1 (Figure 1E, lanes 6–8). Thus, several
lines of evidence suggested that interaction of homocysteinylated
hnRNP-E1 and the 25-nucleotide cis element in the 5#-UTR of
hnRNP-E1mRNA led to an increase in biosynthesis of hnRNP-E1
in vitro, and that the (HA)-hnRNP-E1(C293S) mutant was also
capable of mediating similar effects even in the absence of
homocysteine. Because (HA)-hnRNP-E1(C293S) mutant simi-
larly reacted with the 18-nucleotide folate receptor a mRNA cis
element in the absence of homocysteine (Supplemental Figure 2),
we quantified and compared the RNA-protein interactions
involving these distinct cis elements by formal dissociation
constant studies (Tables 1 and 3). When purified wild-type
hnRNP-E1 was reacted with the 25-nucleotide hnRNP-E1
mRNA cis element in the presence of increasing (physiologically
relevant) concentrations of L-homocysteine, there was a dose-
dependent increase in binding affinity (Table 1); thus, the KD
progressively decreased from a basal value of 1.93 nmol/L (in the
absence of L-homocysteine) to a KD of 1.14 nmol/L and
0.62 nmol/L in the presence of 10 mmol L-homocysteine/L and
50 mmol L-homocysteine/L, respectively (P < 0.05). Moreover,
although the difference in basal KD values between wild-type
hnRNP-E1 and wild-type–like hnRNP-E1(G292A) mutant (in
the absence of L-homocysteine) was not significant (1.93 nmol/L
compared with 2.02 nmol/L, respectively), the (HA)-hnRNP-E1
(C293S) mutant exhibited a significantly higher affinity for the
25-nucleotide hnRNP-E1mRNA cis element even in the absence
of L-homocysteine (KD = 0.39 nM). This reflected a significantly
higher affinity than that observed when the wild-type hnRNP-E1
protein was reacted with the 25-nucleotide hnRNP-E1 mRNA
cis element in the presence of 50 mmol L-homocysteine/L (KD =
0.62 nM).
As expected (3), there was a progressive increase in binding
affinity between wild-type hnRNP-E1 and folate receptor a
mRNA cis element in the presence of increasing concentra-
tions of L-homocysteine (Table 3). Here, too, in the absence of
L-homocysteine, the KD of both wild-type hnRNP-E1 and wild-
type–like hnRNP-E1(G292A) mutant for folate receptor a
mRNA cis element was comparable, i.e., KD = 1.47-nmol/L
compared with 1.57-nmol/L, respectively. However, (HA)-
hnRNP-E1(C293S) mutant exhibited a significantly higher affin-
ity for folate receptor amRNA cis element even in the absence of
L-homocysteine. Again, this value (KD = 0.27 nmol/L) reflected a
significantly higher affinity than the value of the wild-type
hnRNP-E1 for this cis element in the presence of 50 mmol
L-homocysteine/L (KD = 0.47 nmol/L). Taken together, these
data confirmed that 1) as with its interaction with folate receptor
a mRNA cis element (3), homocysteinylated hnRNP-E1 also
bound the 25-nucleotide hnRNP-E1 mRNA cis element with
high affinity at physiologic concentrations of L-homocysteine,
as would be found in mild-to-moderate folate deficiency
in vivo (2, 22, 23); and 2) the (HA)-hnRNP-E1(C293S) mutant
was capable of binding both the hnRNP-E1 mRNA cis element,
as well as the folate receptor a mRNA cis element, with simi-
larly high (but not identical) affinity, even in the absence of
homocysteine.
Posttranscriptional upregulation of hnRNP-E1 in placental
cells involves interaction of the 25-nucleotide hnRNP-E1
cis-element and homocysteinylated hnRNP-E1. Both folate
receptors and hnRNP-E1 were comparably upregulated at the
posttranscriptional level under folate-depleted conditions in
placental JAR and 1584 cell lines (Supplemental Figure 3).
Accordingly, the latter cell line was selected to further charac-
terize the role of a specific RNA-protein interaction in the
posttranscriptional upregulation of hnRNP-E1 within cells. As
shown in Figure 2A and B folate-depleted placental 1584-LF
cells exhibited a 9-fold overexpression of folate receptor pro-
teins, with only a 1.6-fold increase in folate receptor mRNA over
basal values found in folate-replete placental 1584-HF cells.
Likewise, there was a >2-fold increase in hnRNP-E1 protein in
folate-depleted cells, which was associated with only one-third
TABLE 3 Comparison of the KD of the interaction of
recombinant purified GST–hnRNP-E1 or its mutant protein for the
[35S]18-nucleotide folate receptor a mRNA cis element in the
absence or presence of L-homocysteine1
Protein L-homocysteine, mM KD, nM
GST–hnRNP-E1 0 1.47 6 0.16a
GST–hnRNP-E1 10 0.89 6 0.16b
GST–hnRNP-E1 50 0.47 6 0.09c
GST–hnRNP-E1(G292A) 0 1.57 6 0.16a
GST–hnRNP-E1(C293S) 0 0.27 6 0.04d
1 Values are means 6 SDs, n = 3 (means of triplicates). Labeled means without a
common superscript letter differ, P, 0.05. GST, glutathione S-transferase; hnRNP-E1,
wild-type heterogeneous nuclear ribonucleoprotein E1; hnRNP-E1(C293S), highest
affinity–heterogeneous nuclear ribonucleoprotein E1 (C293S)–mutant protein; hnRNP-
E1(G292A), wild-type–like heterogeneous nuclear ribonucleoprotein E1 (G292A)–
mutant protein; KD, dissociation constant.
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the basal expression of hnRNP-E1 mRNA found in folate-
replete cells. Thus, the disproportionately higher folate recep-
tor and hnRNP-E1 protein overexpression compared with
folate receptor and hnRNP-E1 mRNA transcripts suggested
that both of these proteins were upregulated at the posttrans-
criptional level.
Transfection of a control pCAT construct into folate-replete
placental 1584-HF cells did not show a rise in CATactivity under
basal conditions or after incubation with 50-mmol L-homocysteine/L
for 3 h at 37C, as shown in Figure 2C. By contrast, 25-nucleotide
hnRNP-E1 cis element–driven CAT reporter constructs led to a 3-
fold greater CATactivity over control CAT constructs (even without
added homocysteine). This suggested that the basal concentration of
thiols (including cysteine and glutathione and L-homocysteine) extant
in folate-replete cells (1), could be responsible for facilitating
constitutive interaction of endogenous hnRNP-E1 with the 25-
nucleotide hnRNP-E1 cis element–linked CAT reporter (Figure 2C).
Furthermore, when cells transfected with the 25-nucleotide
hnRNP-E1 cis element–driven CATreporter construct were exposed
to 50 mmol L-homocysteine/L for 3 h at 37C, there was a further
significant increase in CAT activity over baseline (Figure 2C). This
confirmed that the interaction of endogenous hnRNP-E1 with the
25-nucleotide hnRNP-E1 cis element would be further increased by
accumulated intracellular L-homocysteine found in clinical folate
deficiency (2). Taken together, these data on placental 1584-HF cells,
which were comparable with earlier studies on the interaction of
homocysteinylated hnRNP-E1 with 18-nucleotide folate receptor a
mRNA cis element in HeLa-IU1 cells (3), predicted that folate
deficiency would similarly trigger the translational upregulation of
hnRNP-E1 through this RNA-protein interaction.
Next, we sought to capture endogenous RNA-protein
complexes composed of hnRNP-E1 mRNA cis element–bound
hnRNP-E1 from either folate-replete placental 1584-HF or
folate-depleted 1584-LF cells, as well as from 1584-HF cells
acutely exposed to L-homocysteine. The specificity of our [35S]
labeled antisense hnRNP-E1 mRNA cis element probe, which
reacted only with hnRNP-E1 plasmids (lane 8), but not with a
plasmid-containing folate receptor a DNA (lane 9), is demon-
strated in Figure 2D. In addition, the 18-nucleotide folate
receptor a mRNA cis element reacted with the folate receptor
a plasmid, but failed to react with the hnRNP-E1 plasmid
(Figure 2E); this confirmed that there were no common
sequences that could result in false positive signals with the
probe used in Figure 2D. There was evidence of hnRNP-E1–
bound hnRNP-E1 mRNA cis element signals signifying the
constitutive existence of RNA-protein complexes within
1584-HF cells, as shown in Figure 2D, lane 1. Furthermore,
experimental induction of the accumulation of L-homocysteine
within placental 1584-HF cells led to a progressive dose-
dependent increase in signal (Figure 2D, lanes 2–5) compared
with baseline values. This reflected the dynamic responsiveness
of this system to L-homocysteine (by formation of additional
RNA-protein complexes). Because 1584-LF cells accumulated
more L-homocysteine than did 1584-HF cells (Figure 3D), this
predicted significantly more intracellular RNA-protein com-
plexes captured from 1584-LF cells, as confirmed in Figure 2D
FIGURE 2 Evidence of posttranscrip-
tional upregulation of hnRNP-E1 (A and B)
and an RNA-protein interaction involving a
25-nucleotide hnRNP-E1 mRNA cis ele-
ment and endogenous hnRNP-E1 pro-
teins in response to homocysteine in
placental 1584 cells (C–E). Western blots
of placental 1584-HF cells (lanes 1 and 3)
and 1584-LF cells (lanes 2 and 4) probed
for FR and hnRNP-E1 (A). One represen-
tative blot of 3 independent experiments
is shown; results of densitometric scan-
ning analysis are presented below the
gels as means 6 SDs, n = 3. Comparison
of the FR RNA and hnRNP-E1 RNA from
1584-HF and 1584-LF cells (B). CAT
reporter activity after transfection of ei-
ther a pCAT construct (denoted ‘‘con-
trol’’) or a 25-nucleotide hnRNP-E1 cis
element–driven CAT reporter construct
(denoted ‘‘25-CAT’’) into 1584-HF cells
before (open bars) and after (shaded bars)
exposure to 50 mmol L-homocysteine/L
(C). Results are presented as means 6
SDs, n = 3 (means of triplicates). Slot-blot
hybridization analysis with the use of a
[35S]-labeled antisense probe to the
25-nucleotide hnRNP-E1 RNA cis ele-
ment (to detect intracellular RNA-protein
complexes composed of the 25-nucleo-
tide hnRNP-E1 RNA cis element bound to hnRNP-E1) after a 2-h exposure of placental 1584-HF cells to increasing concentrations of L-
homocysteine (lanes 1–5) (3), or under basal conditions in 1584-HF and 1584-LF cells (lanes 6 and 7) (D). The 25-nucleotide antisense probe was
reacted with hnRNP-E1 plasmid and an FR plasmid (lanes 8 and 9). Reaction of a [35S]-18-nucleotide FR mRNA cis element probe with an FR
plasmid (lane 2) or hnRNP-E1 plasmid (lane 1) (E). Results of densitometric scans of the signals are shown below the slot-blot and are presented
as means 6 SDs, n = 3. Labeled means without a common letter differ, P , 0.05. *Different from control, P , 0.05. Ab, antiserum; CAT,
chloramphenicol acetyltransferase; FR, folate receptor a; HF, high folate; hnRNP-E1, heterogeneous nuclear ribonucleoprotein E1; IP,
immunoprecipitation with anti–heterogeneous nuclear ribonucleoprotein E1 antiserum; LF, low folate.
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(lane 7 compared with lane 6). Taken together, these results
demonstrated increased specific hybridization signals with a
radiolabeled antisense 25-nucleotide hnRNP-E1 mRNA cis
element probe, which reflected the capture of 25-nucleotide
hnRNP-E1mRNA cis element–bound hnRNP-E1 protein complexes
within placental 1584-HF cells, both constitutively and in response
to L-homocysteine.
Comparison of the effect of various thiols on RNA-protein
interactions. Thereweremuch stronger RNA-protein signals with
100 mmol nonphysiologic thiols/L (DTTand b-mercaptoethanol)
than with physiologic L-homocysteine, as shown in Figure 3A;
however, by contrast, signals with equimolar concentrations of
other physiologic thiols, such as L-cysteine, were far weaker,
and there were no detectable signals with either glutathione or
methionine. Despite the inclusion of physiologically relevant
concentrations of glutathione (10-mmol/L) in the reaction mix-
ture, there was a dose-dependent increase in RNA-protein
complex formation with even 5 mmol/L L-homocysteine.
[During the course of these studies, we noted that recent
batches of commercially available L-homocysteine led to
RNA-protein interactions between hnRNP-E1 and 25-nucleotide
hnRNP-E1 mRNA cis element at lower concentrations than
previously noted (3)].
When the KD of the RNA-protein interaction was tested in
the presence of 10 mmol glutathione/L and equimolar concen-
trations of L-homocysteine and L-cysteine, there was a signifi-
cantly higher affinity obtained with L-homocysteine (quantified
by a lower KD) (Table 4). These studies were generally compa-
rable with RNA-protein interactions involving folate receptor a
mRNA binding to hnRNP-E1 (3).
There was a <2-fold increase in other thiols (cystathionine,
cysteine, and methionine) in 1584-LF cells compared with
in1584-HF cells. However, there was a 5.75-fold increase in
homocysteine in 1584-LF cells compared with in 1584-HF cells
(184-mmol/L compared with 32-mmol/L, respectively) (Figure
3B; Table 5). Thus, although the basal concentration of cysteine
in 1584-HF cells was high (327 mmol/L), and rose only 1.5-fold
more in 1584-LF cells, based on data in Figure 3A, it was not
likely that these concentrations would have had as much
influence in increasing the binding affinity of the RNA-protein
interaction as L-homocysteine, which rose nearly 6-fold in
folate-deficient cells.
Effect of mutation of the 25-nucleotide hnRNP-E1 cis
element on the RNA-protein Interaction. Studies with 18-
nucleotide folate receptor amRNA cis element suggested that
the sequence motif of CUCC in tandem (with intervening
nucleotides) could be important for interaction with hnRNP-E1
(5, 18). Because the 25-nucleotide hnRNP-E1 mRNA cis
element contained 3 such distinct CUCC sequences, we
evaluated the effect of mutating a single nucleotide within
each of these CUCC sequences on the specificity of binding of
hnRNP-E1 to the hnRNP-E1 mRNA cis element with the use
of gel-shift assays. We noted that various mutations (num-
bered 1–5) (Figure 4A and Table 6) led to progressively
quenched RNA-protein interaction signals. Of significance,
mutation no. 6 (involving the first and third CUCC sequences)
led to complete quenching of the signal. Thus, the integrity of
the first and third CUCC sequence motif in the 25-nucleotide
hnRNP-E1 mRNA cis element was critical for interaction
with homocysteinylated hnRNP-E1 in vitro. Moreover, al-
though wild-type 25-nucleotide hnRNP-E1 cis element placed
proximal to the CAT reporter led to progressively increased
and significant CAT reporter signals in response to exoge-
nously added L-homocysteine (Figure 4B), mutation no. 6 of
the hnRNP-E1 mRNA cis element placed proximal to CAT
reporters yielded no such response. Thus, these mutations in
FIGURE 3 Characterization of the influence of various thiols on the interaction of hnRNP-E1 with the 25-nucleotide hnRNP-E1 mRNA cis
element and the accumulation of various thiol amino acids in placental 1584-LF compared with 1584-HF cells. Gel-shift assays on the interaction
of 0.5 mg dialyzed purified recombinant GST–hnRNP-E1 with 1 3 105 counts/min of [35S]25-nucleotide hnRNP-E1 mRNA cis element in the
presence of various indicated thiols (A). The result is representative of 2 studies that gave comparable results. Comparison of the percentage
increase in various thiols in placental 1584-LF over 1584-HF cells (B); the data were taken from Table 5 to highlight the percentage increase in
homocysteine over other thiols in folate-depleted cells. *Different from control, P, 0.05. GST, glutathione S-transferase; HF, high folate; hnRNP-
E1, wild-type heterogeneous nuclear ribonucleoprotein E1; LF, low folate; nt, nucleotide; b-Me, b-mercaptoethanol.
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the 25-nucleotide hnRNP-E1 cis element were also function-
ally relevant within placental cells.
Effect of transfection of specific antisense oligonucleotides
on the biosynthesis of hnRNP-E1. Transfection of wild-
type and scrambled oligonucleotides did not significantly alter
the biosynthetic rate of hnRNP-E1 (similar rates of 1.0 fmol
[35S]cysteine  mg protein21  h21 incorporated into hnRNP-E1);
by contrast, transfection of antisense oligonucleotides to the
25-nucleotide mRNA cis element of hnRNP-E1 led to a signif-
icant reduction in the biosynthetic rate of newly synthesized
hnRNP-E1 of 0.62 fmol [35S]cysteine  mg protein21  h21 incorpo-
rated into hnRNP-E1 (Table 7).
Effect of RNA interference of hnRNP-E1 mRNA on the
biosynthesis of hnRNP-E1. The transfection of siRNA
directed specifically to hnRNP-E1 mRNA, which did not have
an impact on hnRNP-E2 (3), led to less cell death after 2 d, and
achieved an ;60% reduction of hnRNP-E1 mRNA (Figure 5).
Compared with basal control values that used scrambled RNA
that had comparable values as wild-type cells, there was a
significant reduction in rate of biosynthesis of hnRNP-E1 and
folate receptor proteins (Table 8). Specifically, there was a
reduction in the rate of newly synthesized hnRNP-E1 from 0.95
to 0.32 fmol L-[35S]cysteine incorporated into hnRNP-E1  mg
protein21  h21 in scrambled compared with siRNA-treated
cells, respectively (Table 8). Likewise, there was a reduction in
the rate of newly synthesized folate receptor from 1.57 to
0.35 fmol L-[35S]cysteine incorporated into folate receptor  mg
protein21  h21 in scrambled compared with siRNA-treated
cells, respectively (Table 8). This pointed to the specificity of
effects of RNA interference of hnRNP-E1 mRNA on the
biosynthesis of hnRNP-E1 within cells. Moreover, because
folate receptor biosynthesis is mediated by hnRNP-E1 (5),
the coreduction of biosynthesis of folate receptor also verified
the effects of RNA interference of hnRNP-E1 mRNA on the
reduction of hnRNP-E1 (3). These studies unambiguously
confirmed that hnRNP-E1 was directly involved in the cellular
biosynthesis of both hnRNP-E1 and folate receptor proteins.
Moreover, because there was a reduction in the basal rate of
hnRNP-E1 (and folate receptor) biosynthesis even in placental
1584-HF cells, these data suggest that the constitutive expres-
sion of hnRNP-E1 (and folate receptors) in these cells is also
mediated by hnRNP-E1 interaction with both 25-nucleotide
hnRNP-E1 mRNA cis elements and 18-nucleotide folate recep-
tor a mRNA cis elements. Together, the data in Figures 4 and 5
and Tables 7 and 8 further confirm the specificity of the RNA-
protein interaction (involving hnRNP-E1 binding to its own
mRNA cis element) for the biosynthesis of hnRNP-E1 at the
posttranscriptional level in placental 1584-HF cells.
Triggering the biosynthesis of folate receptor and hnRNP-E1
proteins by the introduction of (HA)-hnRNP-E1(C293S)
mutant proteins into cells. (HA)-hnRNP-E1(C293S) mutant
proteins interact with both the 25-nucleotide hnRNP-E1 RNA cis
element and 18-nucleotide folate receptor a mRNA cis element in
the absence of L-homocysteine in vitro (Figure 1, Supplemental
Figure 2, and Tables 1 and 3). Therefore, we tested the potential of
liposome-transfected (HA)-hnRNP-E1(C293S) mutant proteins to
bind to both of these endogenous hnRNP-E1 and folate receptor
mRNA cis elements and trigger the biosynthesis of hnRNP-E1 and
folate receptors in 1584-HF cells (where homocysteine concentra-
tions are at basal levels). Wild-type hnRNP-E1 proteins induced a
significant increase in the biosynthesis of [35S]hnRNP-E1 com-
paredwith basal rates (1.12 comparedwith 0.53 fmol [35S]cysteine
incorporated into hnRNP-E1  mg protein21  h21, respectively)
(Table 9). Similarly, the wild-type–like hnRNP-E1(G292A) mutant
also resulted in a comparable rise in rates of [35S]cysteine–hnRNP-E1
biosynthesis (1.03 fmol  mgprotein21  h21) aswild-type hnRNP-E1.
By contrast, the introduction of (HA)-hnRNP-E1(C293S) mutant
proteins led to a significant (>6-fold) increase in the rate
of biosynthesis of [35S]cysteine–hnRNP-E1 (to 6.70-fmol  mg
protein21  h21). There were also comparable results in the
stimulation of the biosynthesis of newly synthesized [35S]cysteine–
folate receptors after transfection of these proteins into
placental 1584-HF cells (Table 9). Whereas control wild-type
hnRNP-E1 and wild-type–like hnRNP-E1(G292A) mutant pro-
teins comparably stimulated the biosynthesis of [35S]cysteine–folate
receptors (1.62 compared with 1.79 fmol  mg protein21  h21,
respectively) over basal values, the (HA)-hnRNP-E1(C293S) mu-
tant significantly induced a nearly 4-fold increase of [35S]cysteine–
folate receptors (up to 6.62-fmol  mg protein21  h21) over
controls (Table 9). Thus, the transfection of liposomes bearing
purified wild-type, wild-type–like hnRNP-E1(G292A) mu-
tant, and (HA)-hnRNP-E1(C293S) mutant proteins into cells
led to functional interactions with both endogenous 25-nucleotide
hnRNP-E1 mRNA cis elements and 18-nucleotide folate
receptor mRNA cis elements, leading to significantly increased
biosynthesis of hnRNP-E1 and folate receptor proteins,
respectively.
Effect of iron(II) on the interaction between hnRNP-E1 and
the 25-nucleotide hnRNP-E1 mRNA cis element. hnRNP-E1
is an iron(II)-binding protein that directly binds ferrous iron
with micromolar affinity (3:1 ratio of iron to hnRNP-E1) (24,
25). So we evaluated whether iron(II) had a specific modulating
effect in the homocysteine-induced RNA-protein interaction.
The sensitivity of the system was markedly improved by the use
of fresh radiolabeled [35S]25-nucleotide hnRNP-E1 cis element,
freshly opened vials of commercially purchased L-homocysteine
and iron(II), and incubating iron(II) with dialyzed, purified
GST–hnRNP-E1 before the addition of radiolabeled RNA and
TABLE 5 Concentration of various thiol amino acids in placental
1584-HF cells and 1584-LF cells1
Thiol amino acids, mM 1584-HF cells 1584-LF cells
Homocysteine 31.9 6 1.8 184.4 6 1.5*
Cystathionine 19.4 6 0.3 29.1 6 0.3*
Cysteine 327.3 6 5.2 481.2 6 12.6*
Methionine 46.7 6 1.3 69.2 6 1.9*
1 Values are means 6 SDs, n = 3 (means of triplicates). *Different from control (1584-
HF cells), P , 0.05. HF, high folate; LF, low folate.
TABLE 4 KD of the RNA-protein interaction of the [
35S]25-
nucleotide hnRNP-E1 mRNA cis element and purified
recombinant GST–hnRNP-E1 protein in the presence of 10 mmol
glutathione/L and either 15 mmol L-homocysteine/L or 15 mmol
L-cysteine/L1
Thiol, 15 mM KD, nM
L-Homocysteine 1.18 6 0.27a
L-Cysteine 2.38 6 0.56b
1 Values are means 6 SDs, n = 3 (means of triplicates). Labeled means without a
common superscript letter differ, P, 0.05. GST, glutathione S-transferase; hnRNP-E1,
wild-type heterogeneous nuclear ribonucleoprotein E1; KD, dissociation constant.
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L-homocysteine. In the presence of a fixed concentration of
L-homocysteine, iron(II) exerted a dose-dependent inhibitory
effect on the formation of these RNA-protein complexes
(Figure 6A, lanes 2–4). By contrast, iron(III) had no such
influence (Figure 6A, lanes 6–8). The quenching effect of iron
(II) was nearly completely blocked by the addition of 50-mmol
deferoxamine/L to the reaction mixture (Figure 6A, lanes 10–
12); this confirmed the specificity of the inhibitory effect of
iron(II) on the formation of these RNA-protein complexes in
the presence of L-homocysteine. To eliminate the potential of
iron(II) to catalyze oxidation changes in proteins (hnRNP-E1)
and potentially nucleic acids (hnRNP-E1 mRNA cis element)
that could have also led to reduced RNA-protein interaction,
these experiments were repeated in the presence of physio-
logically relevant concentrations of glutathione; under these
conditions, iron(III) is converted to iron(II) at pH 7.0 (26, 27).
Accordingly, when 10 mmol glutathione/L was included in all
reaction mixtures, both iron(II) and iron(III) exerted a com-
parable dose-dependent reduction in RNA-complex forma-
tion on gel-shift assays (Figure 6B, lanes 2–4 compared with
lanes 6–8). The ability of deferoxamine to eliminate the
quenching effect of iron(III) in the presence of glutathione
confirmed the specificity of effect of iron(III) that was
converted to iron(II) (Figure 6B, lanes 10–11). Thus, the
trivial possibility of direct oxidative effects of iron(II) on
hnRNP-E1 or RNA was unlikely. To confirm that this was a
general effect of iron(II) on the capacity of hnRNP-E1 to
interact with other target mRNAs in the presence of L-homocysteine,
we were able to reproduce this effect of iron(II) when
18-nucleotide folate receptor a mRNA cis element was substituted
for the 25-nucleotide hnRNP-E1 mRNA cis element (data not
shown).
Iron(II) also had a dose-dependent impact in quenching the
in vitro translation of hnRNP-E1 in the presence of 4.1-mmol
b-mercaptoethanol/L, as shown in Figure 6C; of significance,
even 0.5–1 mmol iron(II)/L consistently led to a negative effect
compared with basal levels, suggesting that there could be a
physiologic effect within cells. Conversely, deferoxamine
alone did not independently influence in vitro translation of
hnRNP-E1 (Figure 6D); this suggested that there was little
free iron(II) available for chelation within the reticulocyte-
rich lysates. However, deferoxamine, in a dose-dependent
manner, was capable of progressively reversing the (quench-
ing) effect of 25 mmol iron(II)/L on the translation of hnRNP-E1
(Figure 6E, lanes 5–9). An equimolar concentration of
deferoxamine added to iron(II) was also effective in prevent-
ing an inhibitory effect of iron(II) on the translation of
hnRNP-E1 (Figure 6F). Finally, iron(II) induced a dose-
dependent reduction in RNA-protein–binding affinity, as
indicated by the progressive increase in KD (Table 2). Taken
together, these data suggested that whereas hnRNP-E1 readily
reacted with target mRNA cis elements in the presence
L-homocysteine, the prior binding of iron(II) to hnRNP-E1
(24, 25) significantly quenched this L-homocysteine–triggered
RNA-protein interaction.
TABLE 6 Primer sequences for various point mutations within


























1 The point mutation sites (numbered Mutations 1–7) are shown in bold capital letters,
and are also underlined. aagctt, restriction enzyme HindIII site; gaattc, restriction
enzyme EcoRI site; hnRNP-E1, heterogeneous nuclear ribonucleoprotein E1.
FIGURE 4 Effect of specific mutations
within the 25-nucleotide hnRNP-E1 mRNA
cis element on the RNA-protein interaction,
and CAT reporter activity after transfection
into placental 1584-HF cells. Gel-shift assays
to assess the capacity of individual indicated
25-nucleotide hnRNP-E1 RNA mutants gen-
erated in Table 6 (numbered from 1 to 7) to
bind to purified recombinant GST–hnRNP-E1
in the presence of 15 mmol L-homocysteine/L
(A). Comparison of CAT reporter activity after
transfection of either a wild-type 25-nucleotide
hnRNP-E1 cis element–driven CAT reporter con-
struct or a mutated 25-nucleotide hnRNP-E1 cis
element–bearing mutant no. 6–driven CAT
reporter construct into placental 1584-HF
cells (B). Values are means 6 SDs, n = 3
(means of triplicates). Labeled means with-
out a common letter differ, P , 0.05. CAT, chloramphenicol acetyltransferase; GST, glutathione S-transferase; HF, high folate; hnRNP-E1,
wild-type heterogeneous nuclear ribonucleoprotein E1; nt, nucleotide.
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Dual upregulation of hnRNP-E1 and folate receptors in
tumor xenografts propagated in folate-deficient mice.
Because hnRNP-E1 could bind 2 distinct cis elements in cultured
placental cells, we pursued investigations into whether there was
dual upregulation of folate receptors and hnRNP-E1 in vivo in
placentas of pregnant mice fed a folate-deficient diet compared
with folate-replete dams (13). However, there was significant
apoptosis of megaloblastic placental trophoblastic cells in situ,
which led to significant architectural changes only in placentas
of folate-deficient dams (Supplemental Figure 4). Because the
trophoblastic cell mass is also the major locus of expression of
folate receptors and hnRNP-E1, it was not meaningful to
directly compare the expression of folate receptors or the
hnRNP-E1 of placentas between folate-replete and folate-
deficient dams.
Accordingly, we evaluated the possibility of a dual upregu-
lation of both folate receptor and hnRNP-E1 in HeLa-IU1 cell–
derived tumor xenografts in an athymic mouse model (19), in
which the tumor was homogeneous and the folate content of the
murine diet was controlled (13). Mice fed a folate-restricted diet
(120 nmol folate/kg diet) compared with a folate-replete diet
(1200 nmol folate/kg diet) throughout the 4 wk (13) before
injection of HeLa-IU1 cells into their flanks (19) and over the
ensuing 4 wk did not exhibit differences in the amount of food
consumed or their weight. However, the folate-restricted diet
resulted in a serum homocysteine of 185mmol/L (consistent with
severe folate deficiency), which was nearly 10 times more than
the serum homocysteine (19 mmol/L) of control mice (13).
Immunohistochemical studies for tumor hnRNP-E1 expression
with the use of anti–hnRNP-E1 antiserum revealed enhanced
brown staining in folate-deficient xenografts (Figure 7D) com-
pared with folate-replete xenografts (Figure 7C); by contrast,
there was little staining with the use of nonimmune serum
(Figure 7A, B). Compared with tumors from mice fed a folate-
replete diet (Figure 7A, C), tumors that developed in folate-
deficient mice (Figure 7B, D) exhibited megaloblastic features
with larger nuclei and open chromatin and an abundant
cytoplasm (reflecting a high nuclear:cytoplasmic ratio) and
consequently fewer cells per 403 magnification field. Western
blot analysis with the use of anti-folate receptor antiserum, as
well as anti–hnRNP-E1 antiserum, confirmed an increased
signal reflecting upregulation of both folate receptors and
hnRNP-E1 in tumor xenografts of folate-deficient mice. More-
over, northern blots (Figure 7F) showed no difference in mRNA
levels for both folate receptor and hnRNP-E1 mRNA. Thus,
there was evidence of upregulation for both folate receptor and
hnRNP-E1 protein concentrations within the xenografts of
animals that experienced folate deficiency, which likely oc-
curred at the posttranscriptional level. Parenthetically, although
immunohistochemistry of the tumors revealed more abundant
staining of hnRNP-E1 in cytoplasm and nuclei compared with
western blots of tumors (cytosol), the concordance between
these distinctly different methods, which confirmed upregula-
tion of hnRNP-E1 and folate receptors in response to folate
deficiency, was the important finding. These data were also
concordant with those of cultured placental cells propagated in
LF medium, as well as the observed effects of homocysteinylated
hnRNP-E1 and (HA)-hnRNP-E1(C293S) mutant proteins in
triggering the biosynthesis of folate receptors and hnRNP-E1 in
these cells.
Discussion
Perpetuation of hnRNP-E1 biosynthesis during folate
deficiency at the translational level. This paper provides
support for a model that invokes physiologic auto upregulation
of hnRNP-E1 by homocysteinylated hnRNP-E1 during pro-
longed folate deficiency (Figure 8). Thus, during folate defi-
ciency, with an intracellular accumulation of L-homocysteine,
the high affinity interaction of intracellular homocysteinylated
hnRNP-E1 with a 25-nucleotide cis element in the 5#-UTR of
hnRNP-E1mRNA triggers an increase in biosynthesis of hnRNP-E1,
which results in the upregulation of hnRNP-E1 proteins. With
ongoing folate deficiency, newly synthesized hnRNP-E1 would
also become homocysteinylated and perpetuate a positive-
feedback loop, which generates hnRNP-E1 (and folate recep-
tors) for as long as folate deficiency persists (Figure 8). This
amplified and homocysteinylated hnRNP-E1 will also interact
(with varying degrees of affinity) with other mRNA members
of the nutrition-sensitive folate-responsive posttranscriptional
RNA operon during folate deficiency. Because this interaction
is sensitive to low concentrations of L-homocysteine, even the
small amount of hnRNP-E1 generated during mild folate
deficiency could become homocysteinylated and trigger the
translation of additional hnRNP-E1, leading to the amplifica-
tion of this circuit, akin to a ‘‘snowball effect’’ (Figure 8). Con-
versely, relief of folate deficiency will turn off this positive
feedback loop by reactivating one-carbon metabolism and
reducing cellular homocysteine concentrations via conversion
to methionine (2), which has no effect on the RNA-protein
TABLE 7 Effect of transfection of wild-type, scrambled, and
antisense oligonucleotides to the 25-nucleotide hnRNP-E1 mRNA
cis element on the rate of biosynthesis of [35S]cysteine–hnRNP-




fmol  mg protein21  h21
Wild-type 1.04 6 0.02a
Scrambled 1.01 6 0.03a
Antisense 0.62 6 0.02b
1 Values are means 6 SDs, n = 3 (means of triplicates). Means in a column without a
common superscript letter differ, P , 0.05. HF, high folate; hnRNP-E1, wild-type
heterogeneous nuclear ribonucleoprotein E1.
FIGURE 5 Evidence of the specificity of RNAi against hnRNP-E1
mRNA in placental 1584-HF cells. Values are means 6 SDs, n = 3
(means of triplicates). Labeled means without a common letter differ,
P , 0.05. HF, high folate; hnRNP-E1, heterogeneous nuclear ribonu-
cleoprotein E1; RNAi, RNA interference.
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interaction (Figure 8).Meanwhile, the residual homocysteinylated
hnRNP-E1 will eventually be degraded (3) while constitutive
biosynthesis of hnRNP-E1 is reestablished. This posttran-
scriptional upregulation of hnRNP-E1 during folate deficiency
occurs in a manner similar to that of the physiologic upregulation
of folate receptors (3). Therefore, hnRNP-E1 mRNA is yet
another member of this posttranscriptional RNA operon that is
orchestrated by homocysteinylated hnRNP-E1 during folate
deficiency (3).
Although, to our knowledge, the finding that hnRNP-E1
interacts with its own mRNA cis element under physiologic
conditions has not been reported, Waggoner and Liebhaber (29)
earlier noted that aCP2 (also known as hnRNP-E2) mRNAwas
associated with specifically immunoprecipitated aCP2/hnRNP-E2.
However, despite their prescient suggestion of possible autoregu-
latory control of aCP2 expression (29), to our knowledge, no
formal studies had investigated the physiologic basis for this
interaction, particularly as it relates to nutrition. Our data
provide a physiologic context for specific interaction be-
tween homocysteinylated hnRNP-E1 and its own 25-nucleotide
hnRNP-E1 mRNA cis element.
Earlier, we determined that, among the various physiologi-
cally relevant thiols, hnRNP-E1 activation and mRNA-binding
was optimal with L-homocysteine, but far less so with DL–
homocysteine, homocysteine thiolactone, L-cysteine, and gluta-
thione (1, 3, and this paper); however, D-homocysteine and
methionine did not have any effect on triggering this RNA-
protein interaction involving hnRNP-E1 binding to folate
receptor mRNA (1, 5) and hnRNP-E1 mRNA cis element (this
paper), as well as to other known target cis elements (17). Based
on these considerations, it is biologically plausible that other
vitamin deficiencies (of vitamin B-12 and vitamin B-6) and other
genetic defects in folate and cobalamin metabolism, which
likewise result in accumulation of this thiol intracellularly,
would also result in homocysteinylation and activation of
hnRNP-E1 to interact with its target RNA cis elements as a
collateral, but secondary effect, as discussed earlier (3). This
warrants additional study in animal models.
Although in vitro assays that used purified components
revealed that RNA-protein interaction can occur with as low as
2.5 mmol L-homocysteine/L, the precise concentration of free
intracellular homocysteine that can trigger the interaction of
hnRNP-E1 with target mRNA during mild, moderate, and
severe folate deficiency is not known. The current state-of-the-
art assay for measuring homocysteine in biological specimens
detects the sum of all free and protein-bound homocysteine (3),
so that fraction of free homocysteine—and other thiols—that
can react within hnRNP-E1 in cells remains to be determined.
Moreover, distinguishing between that fraction of (activated)
homocysteinylated hnRNP-E1 and unmodified hnRNP-E1 in
cells at different degrees of folate deficiency awaits additional
refinement in the separation of these fractions.
There is some evidence for a potential (albeit minor) role of
hnRNP-E1 in the transcription of folate receptor (1, 3, 5).
However, because Mayanils laboratory has determined that the
folate receptor itself is a transcription factor (30), and ampli-
fication of hnRNP-E1 during prolonged folate deficiency affects
the upregulation of folate receptors (3 and this paper), it will be
of interest to identify the entire repertoire of downstream genes
that are independently transcribed by hnRNP-E1 and folate
receptors during folate deficiency.
Because homocysteine that accumulates in cells leaks out (1)
and median values for elevation of serum homocysteine among
several cohorts with clinical folate and vitamin B-12 deficiency
is ;50 and 70 mmol/L, respectively (22, 23, 28), such concen-
trations are capable of homocysteinylation of intracellular
hnRNP-E1 and triggering high affinity RNA-protein interac-
tions in vivo. This predicts the upregulation of hnRNP-E1 and
posttranscriptional engagement of mRNAs comprising its post-
transcriptional RNA operon in both vitamin B-12 and folate
deficiency (2, 22, 23, 28). Indeed, the common clinical hema-
tologic manifestations of folate and vitamin B-12 deficiency
TABLE 9 Effect of the introduction of equivalent amounts of various purified recombinant wild-type or mutant GST–hnRNP-E1
proteins into placental 1584-HF cells on the biosynthetic rate of newly synthesized [35S]cysteine–hnRNP-E1 and [35S]cysteine–folate
receptor proteins1
Protein transfected in
placental 1584-HF cells [35S]cysteine–hnRNP-E1, fmol  mg protein21  h21 [35S]cysteine–folate receptor, fmol  mg protein21  h21
No transfection 0.53 6 0.17a 0.95 6 0.12a
GST–hnRNP-E1 1.12 6 0.23b 1.62 6 0.11b
GST–hnRNP-E1(G292A) 1.03 6 0.21b 1.79 6 0.13b
GST–hnRNP-E1(C293S) 6.70 6 1.74c 6.62 6 0.74c
1 Values are means 6 SDs, n = 3 (means of triplicates). Means without a common superscript letter differ, P , 0.05. GST, glutathione S-transferase; HF, high folate; hnRNP-E1,
wild-type heterogeneous nuclear ribonucleoprotein E1; hnRNP-E1(C293S), highest affinity–heterogeneous nuclear ribonucleoprotein E1 (C293S)–mutant protein; hnRNP-E1(G292A),
wild-type–like heterogeneous nuclear ribonucleoprotein E1 (G292A)–mutant protein.
TABLE 8 Evidence of the specificity of RNAi against hnRNP-E1 mRNA in perturbing the biosynthetic rate of newly synthesized
hnRNP-E1 and folate receptor proteins in placental 1584-HF cells1
RNAi transfected in
placental 1584-HF cells [35S]cysteine–hnRNP-E1, fmol  mg protein21  h21 [35S]cysteine–folate receptor, fmol  mg protein21  h21
Wild-type 25-nucleotide hnRNP-E1 RNA 1.02 6 0.07a 1.58 6 0.02a
Scrambled 25-nucleotide RNA 0.95 6 0.04a 1.57 6 0.05a
RNAi against 25-nucleotide hnRNP-E1 mRNA 0.32 6 0.02b 0.35 6 0.02b
1 Values are means 6 SDs, n = 3 (means of triplicates). Means in a column without a common superscript letter differ, P , 0.05. HF, high folate; hnRNP-E1, heterogeneous
nuclear ribonucleoprotein E1; RNAi, RNA interference.
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likely involve contributions from this nutrition-sensitive post-
transcriptional RNA operon.
Our data on the upregulation of folate receptors in HeLa-
IU1–derived tumors growing in folate-deficient mice are
consistent with the studies by Leamon et al. (31). However, our
findings that the dual upregulation of folate receptors and
hnRNP-E1 likely occurred at the posttranscriptional level in
both placental cells and tumor xenografts in response to folate
deficiency suggested that endogenous homocysteinylated
hnRNP-E1 likely bound to 2 distinct mRNA cis elements in the
same tissue. This was corroborated by experiments involving the
modulation of hnRNP-E1 within folate-replete placental cells
that used siRNA against hnRNP-E1 mRNA and (HA)-hnRNP-
E1(C293S) mutant proteins. These results can now explain the
constitutive coexpression of these 2 proteins in several human
tissues, such as the placenta (4, 5), cervix (1, 6), reticulocytes,
and erythroid precursors (7–12), as well as in several murine
fetal tissues of dams that experienced gestational folate defi-
ciency (13). Although homogeneous populations of tumor
xenografts had uniform upregulation of hnRNP-E1 in response
to folate deficiency, there was selective expression of hnRNP-E1
in heterogeneous tissues in different organs from murine fetuses
FIGURE 6 Characterization of the specific effect of iron(II) or iron(III) on the L-homocysteine–triggered RNA-protein interaction involving
25-nucleotide hnRNP-E1 mRNA cis element and purified recombinant GST–hnRNP-E1 by gel-shift assay (A and B) and in vitro translation assay
(C–F). Effect of iron(II) or iron(III) on the RNA-protein interaction in the absence (A) or presence (B) of 10 mM glutathione. Effect of the addition of
either iron(II) (C), deferoxamine (D), or varying combinations of iron(II) and deferoxamine (E and F) on the translation of hnRNP-E1 in vitro. Each of
these representative gels is from 3 independent sets of experiments that gave comparable data with ,10% variation. The pooled densitometric
scanned data from 3 independent experiments (A–C) are shown as a bar graph below one representative gel; values are means 6 SDs, n = 3.
Labeled means without a common letter differ, P , 0.05. In each panel, uppercase letters are compared only with other uppercase letters, and
lowercase letters are compared only with other lowercase letters. DFO, deferoxamine; GST, glutathione S-transferase; hnRNP-E1, wild-type
heterogeneous nuclear ribonucleoprotein E1; iron(II), ferrous sulfate heptahydrate; iron(III), ferric chloride hexahydrate; nt, nucleotide.
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that experienced folate deficiency in utero (Supplemental Figure 5).
Future experiments will need to clarify the basis for these
selective transcriptional and/or posttranscriptional events that
contributed to these observations.
Effect of iron(II) in modulating the RNA-protein interaction.
Although hnRNP-E1 (also known as PCBP1) is a cellular
sensor of folate deficiency (3), it is also an iron-binding protein
that is believed to chaperone cytosolic iron to ferritin (24, 25).
Although both cysteine and glutathione are candidate ligands
for the cytosolic labile iron pool, and bind iron(II) with high
affinity (26, 27), the much higher physiologic concentration of
glutathione (10 mmol/L) than that of cysteine (<0.5 mmol/L)
will dominate the binding of iron. Indeed, Hider and Kong
(26, 27) suggested that themajor component of the labile iron pool
in the cytosol is the simple glutathione-Fe(II) complex, and that
this complex will dominate the speciation of iron(II) over cellular
iron(II) concentrations of 1027 to 1025. We observed that, in the
presence of a fixed concentration of L-homocysteine that triggered
homocysteinylated hnRNP-E1 binding to hnRNP-E1 mRNA cis
element, there was a specific dose-dependent effect of iron(II) in
quenching this interaction. Although iron(III) alone had no effect
in modulating RNA-protein complex formation, when iron(III)
was rapidly reduced to iron(II) by 10 mmol glutathione/L (26, 27),
there was a similar specific effect [as iron(II)] in reducing the
interaction of homocysteinylated hnRNP-E1 with hnRNP-E1
mRNA cis element. The molecular basis for the effect of iron(II)
and glutathione-Fe(II) complex on hnRNP-E1 remains to be
clarified.
Despite these findings, it remains unclear whether these
effects of the addition of iron(II) evoked experimentally with the
use of purified components are biologically relevant in iron-
replete cells. This is because all our previous studies involving
hnRNP-E1 that documented significant posttranscriptional
upregulation of folate receptors in cells (3), and upregulation
of hnRNP-E1 in murine fetuses of dams that experienced
gestational folate deficiency (13), as well as in cultured placental
cells and xenografts in mice (this paper), were conducted under
conditions with sufficient iron(II) present. However, a more
plausible and clinically relevant scenario inwhich a role of iron(II)
can be better appreciated is during combined iron and folate
deficiency, which is found in well over one-half of pregnant
women in resource-limited countries (2, 22, 32, 33). In such a
scenario, the reduced intracellular availability of iron(II) to
interact with hnRNP-E1 would be permissive in facilitating the
capacity of L-homocysteine to covalently bind to hnRNP-E1 and
unmask its mRNA-binding site, leading to an increased binding
affinity for target mRNA (Figure 8). Therefore, the net effects of
iron(II) deficiency—when superimposed on a given degree of
folate deficiency—could be to further enhance the engagement
of member mRNAs (of the nutrition-sensitive posttranscrip-
tional RNA operon) by homocysteinylated hnRNP-E1; this
could lead to even more adverse effects than the effects of pure
folate deficiency (i.e., iron deficiency has the potential to
magnify the adverse effects of folate deficiency). This hypothesis
warrants further testing in vivo in animals with combined folate
and iron deficiency, particularly because of its potential rele-
vance to fetal neurodevelopment. For example, we documented
a dose-dependent interaction of homocysteinylated hnRNP-E1
with tyrosine hydroxylase and neuronal intermediate neurofilament–
middle molecular mass (neurofilament M) mRNAs, which was
associated with overexpression of tyrosine hydroxylase and
neurofilament M proteins, respectively, in the brains of murine
fetuses that experienced folate deficiency (3). Therefore, in a
fetus that experiences combined iron and folate deficiency, the
augmented interaction of homocysteinylated hnRNP-E1 with
tyrosine hydroxylase mRNA (3) could lead to an even greater
overexpression of tyrosine hydroxylase (34, 35) and predispo-
sition to increased biosynthesis of neurotransmitters (dopamine
and norepinephrine). Likewise, the augmented interaction of
homocysteinylated hnRNP-E1 with neurofilament M mRNA,
leading to greater overexpression of neurofilament M (3), could
further perturb its delicately balanced synthesis with neurofilament
low- and high-molecular-mass triplet proteins, resulting in
abnormal intermediate filaments and disturbed formation of
neurons (36–42). Thus, assessing how the superimposition of
iron deficiency to folate deficiency can further worsen the
already disordered histopathology in the brains of mouse
FIGURE 7 Dual upregulation of hnRNP-E1 and FRs at the post-
transcriptional level in HeLa-IU1–derived tumor xenografts of mice fed
either a folate-replete diet (A and C) or a folate-deficient diet (B and D)
for 1 mo before and after implantation of 1 million HeLa-IU1 cells into
their flanks. Because of prohibitive costs, this longitudinal experiment
was carried out only once; similar results were obtained from 2
randomly selected tumors each from folate-replete mice (n = 6) and
folate-deficient mice (n = 5). Immunohistochemistry for hnRNP-E1
with the use of nonimmune serum (A and B) compared with anti–
hnRNP-E1 antiserum (C and D). Magnification was 403. Western
blots (50-mg tumor protein probed with either anti-folate receptor
antiserum, anti–hnRNP-E1 antiserum, or anti-GAPDH antibodies) to
assess the expression of folate receptor and hnRNP-E1 in the tumor
(E). Densitometric evaluation of folate receptor and hnRNP-E1 protein
signals in relation to GAPDH is shown below the gels. Northern blots
(20 mg total tumor RNA) to assess FR a mRNA and hnRNP-E1 mRNA
in tumor xenografts (F). Densitometric scanning of the signals from
northern blots was adjusted by a loading control (b-actin) and is shown
below the gel. The HF diet contained 1200 nmol folate/kg; the LF diet
contained 400 nmol folate/kg. FR, folate receptor; hnRNP-E1, heter-
ogeneous nuclear ribonucleoprotein E1.
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fetuses that experienced folate deficiency in utero (13), and
studying how these dual deficiencies can further modulate their
postnatal anxiety phenotype (43), warrant further investiga-
tion. This is particularly relevant because of 1) the burgeoning
literature pointing to clinical correlates of our murine studies
(3, 13, 43), in which women with dietary insufficiency of
folate during pregnancy appear to have a higher risk of bearing
children with neuropsychiatric and/or behavioral problems (44–
48), and 2) the widespread prevalence of iron deficiency during
pregnancy and acknowledgment of the critical role of iron
during human neurodevelopment (49–58).
The spectrum of mRNAs bound by hnRNP-E1 during
folate deficiency. Although the precise number of mRNAs that
can interact with homocysteinylated hnRNP-E1 is unclear, earlier
studies demonstrated 160 mRNAs that interact with the closely
related protein, aCP2 (hnRNP-E2), in a human hematopoietic cell
line (28). These mRNAs encoded a plethora of cellular proteins,
including those related to components of the cytoskeleton, transcrip-
tion factors, proto-oncogenes, factors involved in cell signaling,
constituents of hemoglobin, and cell proliferation, differentiation,
and apoptosis. Because of significant homology in the K-homology
domains of hnRNP-E2 and hnRNP-E1 (3), such data predict that
the mRNA-binding domain of hnRNP-E1 will also interact with a
comparably large number ofmRNAs. Indeed, several other studies
indicate that hnRNP-E1 interacts with mRNAs involved in cell
differentiation, viral mRNAs, neurotransmitters, nerve and neu-
ronal cell components, and cell cycle proteins (1, 3, 5, 8, 9, 14, 15,
17, 18, 21, 36, 59–71). Parenthetically, in every instance in which
hnRNP-E1 binds these various mRNAs in the presence of non-
physiologic reducing agents such as DTT and b-mercaptoethanol,
there is also an interaction with the physiologically relevant
reducing agent, L-homocysteine (1, 3, 5, 18). So it is clearly
important to identify the entire spectrum ofmRNAmembers of this
posttranscriptional RNA operon that interact with homocysteiny-
lated hnRNP-E1. Another challenge from a pathobiological stand-
point is to identify the rank-order and temporal sequence of binding
of these diverse mRNAs to hnRNP-E1 as it is progressively
homocysteinylated during mild, moderate, and severe clinical folate
deficiency. This is because the net effects of up- and downregulation
of the proteins encoded by the many different mRNAs belonging to
this operon are likely to influence several aspects of the cellular
pathobiology of evolving megaloblastic changes during progressive
folate deficiency.
Potential clinical consequences of perturbed RNA-protein
interactions. Subtle mutations in several members of the hnRNP
family have given rise to diverse clinical syndromes. This includes
fragile X syndrome arising from mutations in the fragile X mental
retardation 1 (FMR1) gene on the X chromosome, results in a
failure to express the fragile X mental retardation protein that
is required for normal neural development. Other paraneoplas-
tic neurologic disorders involving antibodies directed against
one member of the hnRNP family, Nova-1, trigger the clinical
syndrome of paraneoplastic opsoclonus myoclonus ataxia (72,
73), whereas antibodies to another member, Hu neuronal
antigen, induce subacute sensory neuropathy/encephalomyelop-
athy syndrome (74). Thus, in analogy, our data suggest that it is
possible for single nucleotide mutations in either the hnRNP-E1
mRNA cis element or the hnRNP-E1 protein to profoundly
perturb physiologic RNA-protein interaction and result in novel
clinical syndromes. For example, mutations in the first and/or
third CUCC motif of the 25-nucleotide hnRNP-E1 mRNA cis
element would reduce or abolish interaction with hnRNP-E1
(Figure 4). Conversely, the mutation of a single cysteine among
several potential cysteine residues in hnRNP-E1 (Supplemental
Figure 2) that leads to an (HA)-hnRNP-E1(C293S)–like mutant
has the potential to markedly increase interaction with operon-
associated mRNAs. Such mutations could give rise to pro-
foundly distinct clinical syndromes that arise from quantitatively
different (and/or opposing) expression of key proteins encoded
by mRNAs that belong to the posttranscriptional RNA operon
controlled by hnRNP-E1 (1, 3, 5, 8, 9, 14, 15, 17, 18, 21, 36,
59–71). Therefore experimental studies in animals bearing such
mutations could provide clues to clinical syndromes in humans
for which the genetic basis has remained obscure.
FIGURE 8 A model for the interaction
between the 25-nucleotide hnRNP-E1mRNA
cis element and homocysteinylated hnRNP-
E1, which amplifies hnRNP-E1 (and thereby
facilitates ongoing upregulation of folate re-
ceptors during prolonged folate deficiency).
The cellular accumulation of homocysteine
during folate deficiency (2, 22, 23, 28) results
in homocysteinylation of hnRNP-E1 (short
broad arrow), which unmasks a high affinity
mRNA-binding site for target mRNAs (3). In
the event of interaction of homocysteinylated
hnRNP-E1 with its own 25-nucleotide hnRNP-
E1 mRNA cis element, this positive-feedback
loop will continue to generate more hnRNP-
E1, resulting in the amplification of hnRNP-E1.
In this model, only folate replenishment can
reduce cellular homocysteine concentrations
to a basal state that will turn off this
autoregulatory positive feedback loop involv-
ing hnRNP-E1 (3). The mRNA-binding site in
homocysteinylated hnRNP-E1 also accommodates several diverse mRNAs (some of these are identified as ‘‘mRNA cis elements’’). The interaction
with these and other mRNA members of the nutrition-sensitive posttranscriptional RNA operon (1, 3, 5, 17) with homocysteinylated hnRNP-E1 will
result in either up- or downregulation of these mRNA-encoded proteins, many of which may contribute to the cellular features observed in folate-
deficient megaloblastic cells. The effect of iron(II) on hnRNP-E1 and other enzyme pathways leading to the intracellular accumulation of
L-homocysteine is not shown. hnRNP-E1, heterogeneous nuclear ribonucleoprotein E1; HPV16, human papillomavirus type 16; iron(II), ferrous
sulfate heptahydrate; neurofilament-M, neuronal intermediate neurofilament–middle molecular mass; nt, nucleotide; 5#-UTR, 5#-untranslated region.
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Finally, the putative homocysteinylation of other members of the
hnRNP family, which are closely related to hnRNP-E1 [such as
hnRNP-E2 (3, 75), and Nova-1 (76), among others], could result in
the activation of a coordinated network of posttranscriptional RNA
operons that together comprise a higher-order, nutrition-sensitive,
folate-responsive, posttranscriptional RNA regulon (3, 16, 17, 77).
In such a construct, the degree to which the mRNA-binding site in
each related hnRNP protein is unmasked by homocysteinylation
will dictate the extent of its participation in such a putative regulon.
In this context, the profound pathophysiologic changes observed in
the murine fetal brain that experienced folate deficiency (3, 13), as
well as the postnatal behavioral features of anxiety (43), could
well have arisen from the activation >1 of these putatively
homocysteinylated hnRNP family members in utero.
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